Arkolith/Insider Trading/PHAS/Form 4

Birchall Jonathan

Chief Commercial OfficerPhaseBio Pharmaceuticals Inc (PHAS) · full profile →Form 4 · filed Feb 28, 2022
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
2
0 non-derivative · 2 derivative

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Feb 24, 2022Grant(A)53K—$053K
Feb 24, 2022Grant(A)11K—$011K

Transaction Codes

A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001169245-22-000013) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML